These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38767403)

  • 21. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
    Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
    Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N; Uner A; Benekli M; Barista I
    Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Long-term complete remission of HIV-negative primary testicular plasmablastic lymphoma treated with bortezomib in combination with EPOCH].
    Fujishima T; Kawabata Y; Michishita Y; Kitabayashi A; Takahashi N
    Rinsho Ketsueki; 2022; 63(10):1386-1391. PubMed ID: 36351644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
    Godfrey JK; Nabhan C; Karrison T; Kline JP; Cohen KS; Bishop MR; Stadler WM; Karmali R; Venugopal P; Rapoport AP; Smith SM
    Cancer; 2019 Jun; 125(11):1830-1836. PubMed ID: 30707764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.
    Tzankov A; Leu N; Muenst S; Juskevicius D; Klingbiel D; Mamot C; Dirnhofer S
    J Hematol Oncol; 2015 Jun; 8():70. PubMed ID: 26071053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
    Davies A; Cummin TE; Barrans S; Maishman T; Mamot C; Novak U; Caddy J; Stanton L; Kazmi-Stokes S; McMillan A; Fields P; Pocock C; Collins GP; Stephens R; Cucco F; Clipson A; Sha C; Tooze R; Care MA; Griffiths G; Du MQ; Westhead DR; Burton C; Johnson PWM
    Lancet Oncol; 2019 May; 20(5):649-662. PubMed ID: 30948276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment.
    Marvyin K; Tjønnfjord EB; Breland UM; Tjønnfjord GE
    BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32994268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Orbital plasmablastic lymphoma--comparison of a newly reported entity with diffuse large B-cell lymphoma of the orbit.
    Morley AM; Verity DH; Meligonis G; Rose GE
    Orbit; 2009; 28(6):425-9. PubMed ID: 19929677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of diffuse large B-cell lymphoma].
    Gleissner B; Zwick C; Pfreundschuh M
    Dtsch Med Wochenschr; 2008 Sep; 133(36):1785-94; quiz 1795-6. PubMed ID: 18767006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.
    Cheng L; Song Q; Liu M; Wang Y; Yi H; Qian Y; Xu P; Cheng S; Wang C; Wang L; Zhao W
    Front Immunol; 2021; 12():702593. PubMed ID: 34322131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
    Till BG
    Curr Treat Options Oncol; 2018 Jul; 19(9):45. PubMed ID: 30032463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of HIV-Associated Lymphomas: The Latest Approaches for Optimizing Outcomes.
    Hunter NB; Vogt S; Ambinder RF
    Oncology (Williston Park); 2017 Dec; 31(12):872-7, 884. PubMed ID: 29297171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement.
    Kojima M; Amaki J; Ogiya D; Ando K; Nakamura N
    J Clin Exp Hematop; 2020 Jun; 60(2):60-61. PubMed ID: 32404573
    [No Abstract]   [Full Text] [Related]  

  • 37. MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.
    Lai C; Roschewski M; Melani C; Pittaluga S; Shovlin M; Steinberg SM; Dunleavy K; Pack S; Jaffe ES; Wilson WH
    Leuk Lymphoma; 2018 Feb; 59(2):505-508. PubMed ID: 28641474
    [No Abstract]   [Full Text] [Related]  

  • 38. Testicular Plasmablastic Lymphoma in an HIV-Negative Patient: A Rare Case Presentation.
    Nwanwene K; Khan NAJ; Alsharedi M
    J Investig Med High Impact Case Rep; 2021; 9():23247096211017423. PubMed ID: 34032157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.
    Sha C; Barrans S; Cucco F; Bentley MA; Care MA; Cummin T; Kennedy H; Thompson JS; Uddin R; Worrillow L; Chalkley R; van Hoppe M; Ahmed S; Maishman T; Caddy J; Schuh A; Mamot C; Burton C; Tooze R; Davies A; Du MQ; Johnson PWM; Westhead DR
    J Clin Oncol; 2019 Jan; 37(3):202-212. PubMed ID: 30523719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management.
    Castillo JJ; Beltran BE; Miranda RN; Young KH; Chavez JC; Sotomayor EM
    Am J Hematol; 2018 Jul; 93(7):953-962. PubMed ID: 29984868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.